L’anticorps anti-ICOSLG Monoclonal Souris est utilisé pour la détection de ICOSLG dans des échantillons de Humain. Il a été validé pour ELISA, FACS, IF et IHC (p).
Optimal dilution of the ICOSLG antibody should be determined by the researcher. 1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
Restrictions
For Research Use only
Format
Liquid
Concentration
0.2 mg/mL
Buffer
0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced) and 0.05 % sodium azide
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Stock
4 °C,-20 °C
Stockage commentaire
Store the ICOSLG antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).
This MAb recognizes a protein of 36 kDa, identified as ICOSLG, which is also known as B7-related protein-1 (B7RP-1).T-cell co-stimulatory molecule, inducible co-stimulator (ICOS)/B7-related protein-1 (B7RP-1, B7-H2, GL50, ICOS-L) is a ligand for the ICOS receptor that initiates T and B cell proliferation and cytokine secretion. ICOS-L interactions play an essential role in T cell-dependent B cell activation in peripheral lymphoid organs such as spleen and lymph nodes. ICOS-L protein is present in myeloid leukocytes, and by northern blot there are 2.4, 3.0, and 7.0 kb transcripts in brain, heart, kidney, and liver, with lower expression in colon and thymus, and a 1.1 kb transcript in leukocytes. Tumor necrosis factor alpha (TNFi±), granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) enhance its expression. LPS-induced up-regulation of ICOS-L is dependent on the MyD88-dependent signaling pathway.